-
Je něco špatně v tomto záznamu ?
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma
R. Koch, H. Gelderblom, L. Haveman, B. Brichard, H. Jürgens, S. Cyprova, H. van den Berg, W. Hassenpflug, A. Raciborska, T. Ek, D. Baumhoer, G. Egerer, HT. Eich, M. Renard, P. Hauser, S. Burdach, J. Bovee, F. Bonar, P. Reichardt, J. Kruseova, J....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
Odkazy
PubMed
35427190
DOI
10.1200/jco.21.01942
Knihovny.cz E-zdroje
- MeSH
- busulfan analogy a deriváty MeSH
- chemoterapie konsolidační MeSH
- cyklofosfamid MeSH
- dítě MeSH
- doxorubicin MeSH
- etoposid MeSH
- Ewingův sarkom * farmakoterapie MeSH
- lidé MeSH
- melfalan MeSH
- mladiství MeSH
- přežití po terapii bez příznaků nemoci MeSH
- prospektivní studie MeSH
- protokoly antitumorózní kombinované chemoterapie škodlivé účinky MeSH
- vinkristin MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
PURPOSE: Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS). METHODS: Phase III, open-label, prospective, multicenter, randomized controlled clinical trial. Eligible patients had disseminated EWS with metastases to bone and/or other sites, excluding patients with only pulmonary metastases. Patients received six cycles of vincristine, ifosfamide, doxorubicin, and etoposide induction and eight cycles of vincristine, actinomycin D, and cyclophosphamide consolidation therapy. Patients were randomly assigned to receive additional TreoMel-HDT or no further treatment (control). The random assignment was stratified by number of bone metastases (1, 2-5, and > 5). The one-sided adaptive-inverse-normal-4-stage-design was changed after the first interim analysis via Müller-Schäfer method. RESULTS: Between 2009 and 2018, 109 patients were randomly assigned, and 55 received TreoMel-HDT. With a median follow-up of 3.3 years, there was no significant difference in EFS between TreoMel-HDT and control in the adaptive design (hazard ratio [HR] 0.85; 95% CI, 0.55 to 1.32, intention-to-treat). Three-year EFS was 20.9% (95% CI, 11.5 to 37.9) in TreoMel-HDT and 19.2% (95% CI, 10.8 to 34.4) in control patients. The results were similar in the per-protocol collective. Males treated with TreoMel-HDT had better EFS compared with controls: median 1.0 years (95% CI, 0.8 to 2.2) versus 0.6 years (95% CI, 0.5 to 0.9); P = .035; HR 0.52 (0.28 to 0.97). Patients age < 14 years benefited from TreoMel-HDT with a 3-years EFS of 39.3% (95% CI, 20.4 to 75.8%) versus 9% (95% CI, 2.4 to 34); P = .016; HR 0.40 (0.19 to 0.87). These effects were similar in the per-protocol collective. This observation is supported by comparable results from the nonrandomized trial EE99R3. CONCLUSION: In patients with very high-risk EWS, additional TreoMel-HDT was of no benefit for the entire cohort of patients. TreoMel-HDT may be of benefit for children age < 14 years.
2nd Department of Pediatrics Semmelweis University Budapest Hungary
British Columbia Cancer Research Centre Vancouver BC Canada
Centre for Clinical Trials Muenster University of Muenster Muenster Germany
Charles University Motol Children's Hospital Prague Czech Republic
Childhood Cancer Center Queen Silvia Children's Hospital Gothenburg Sweden
Chris O'Brien Lifehouse Camperdown Australia
Clinic of Orthopedics University Hospital Essen West German Cancer Centre Essen Germany
Department of Clinical Radiology Klinikum Ibbenbüren Ibbenbüren Germany
Department of Clinical Sciences Skåne University Hospital Lund Sweden
Department of Internal Medicine 5 Heidelberg University Hospital Heidelberg Germany
Department of Medical Oncology Chris O'Brien Lifehouse Sydney Australia
Department of Medical Oncology Leiden University Medical Center Leiden the Netherlands
Department of Medical Oncology Sarcoma Center University of Duisburg Essen Essen Germany
Department of Oncology and Hematology University Children's Hospital Basel Basel Switzerland
Department of Oncology and Palliative Care Helios Klinikum Berlin Buch Berlin Germany
Department of Orthopaedics Semmelweis University Budapest Hungary
Department of Pathology Leiden University Medical Center Leiden the Netherlands
Department of Pediatrics University Hospital Erlangen Erlangen Germany
Department of Radiation Oncology University Hospital Muenster Muenster Germany
Department of Solid Tumors Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
Department of Thoracic Surgery Ruhrlandklinik University Hospital Essen Essen Germany
Douglass Hanly Moir Pathology Macquarie Park Australia
Faculty of Medicine and Health University of Sydney Sydney Australia
German Consortium for Translational Cancer Research German Cancer Research Centre Essen Germany
Institute of Biostatistics and Clinical Research University of Muenster Muenster Germany
Institute of Clinical Medicine Vilnius University Vilnius Lithuania
Paediatrics 3 University Hospital Essen Essen Germany
Pediatric Hematology and Oncology University Hospital Eppendorf Hamburg Germany
Pediatric Hematology and Oncology University Hospital Leuven Gasthuisberg Leuven Belgium
Sydney Medical School University of Sydney Sydney Australia
West German Cancer Centre Network Essen and Muenster Germany
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025177
- 003
- CZ-PrNML
- 005
- 20240219134257.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1200/JCO.21.01942 $2 doi
- 035 __
- $a (PubMed)35427190
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Koch, Raphael $u Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany $1 https://orcid.org/0000000255815122
- 245 10
- $a High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma / $c R. Koch, H. Gelderblom, L. Haveman, B. Brichard, H. Jürgens, S. Cyprova, H. van den Berg, W. Hassenpflug, A. Raciborska, T. Ek, D. Baumhoer, G. Egerer, HT. Eich, M. Renard, P. Hauser, S. Burdach, J. Bovee, F. Bonar, P. Reichardt, J. Kruseova, J. Hardes, T. Kühne, T. Kessler, S. Collaud, M. Bernkopf, T. Butterfaß-Bahloul, C. Dhooge, S. Bauer, J. Kiss, M. Paulussen, A. Hong, A. Ranft, B. Timmermann, J. Rascon, V. Vieth, J. Kanerva, A. Faldum, M. Metzler, W. Hartmann, L. Hjorth, V. Bhadri, U. Dirksen
- 520 9_
- $a PURPOSE: Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS). METHODS: Phase III, open-label, prospective, multicenter, randomized controlled clinical trial. Eligible patients had disseminated EWS with metastases to bone and/or other sites, excluding patients with only pulmonary metastases. Patients received six cycles of vincristine, ifosfamide, doxorubicin, and etoposide induction and eight cycles of vincristine, actinomycin D, and cyclophosphamide consolidation therapy. Patients were randomly assigned to receive additional TreoMel-HDT or no further treatment (control). The random assignment was stratified by number of bone metastases (1, 2-5, and > 5). The one-sided adaptive-inverse-normal-4-stage-design was changed after the first interim analysis via Müller-Schäfer method. RESULTS: Between 2009 and 2018, 109 patients were randomly assigned, and 55 received TreoMel-HDT. With a median follow-up of 3.3 years, there was no significant difference in EFS between TreoMel-HDT and control in the adaptive design (hazard ratio [HR] 0.85; 95% CI, 0.55 to 1.32, intention-to-treat). Three-year EFS was 20.9% (95% CI, 11.5 to 37.9) in TreoMel-HDT and 19.2% (95% CI, 10.8 to 34.4) in control patients. The results were similar in the per-protocol collective. Males treated with TreoMel-HDT had better EFS compared with controls: median 1.0 years (95% CI, 0.8 to 2.2) versus 0.6 years (95% CI, 0.5 to 0.9); P = .035; HR 0.52 (0.28 to 0.97). Patients age < 14 years benefited from TreoMel-HDT with a 3-years EFS of 39.3% (95% CI, 20.4 to 75.8%) versus 9% (95% CI, 2.4 to 34); P = .016; HR 0.40 (0.19 to 0.87). These effects were similar in the per-protocol collective. This observation is supported by comparable results from the nonrandomized trial EE99R3. CONCLUSION: In patients with very high-risk EWS, additional TreoMel-HDT was of no benefit for the entire cohort of patients. TreoMel-HDT may be of benefit for children age < 14 years.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
- 650 _2
- $a busulfan $x analogy a deriváty $7 D002066
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a chemoterapie konsolidační $7 D060830
- 650 _2
- $a cyklofosfamid $7 D003520
- 650 _2
- $a přežití po terapii bez příznaků nemoci $7 D018572
- 650 _2
- $a doxorubicin $7 D004317
- 650 _2
- $a etoposid $7 D005047
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melfalan $7 D008558
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a Ewingův sarkom $x farmakoterapie $7 D012512
- 650 _2
- $a vinkristin $7 D014750
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gelderblom, Hans $u Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands $1 https://orcid.org/0000000192708636
- 700 1_
- $a Haveman, Lianne $u Department of Solid Tumors, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $1 https://orcid.org/0000000185198906
- 700 1_
- $a Brichard, Benedicte $u Department of Pediatric Haematology and Oncology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium $1 https://orcid.org/0000000327651711
- 700 1_
- $a Jürgens, Heribert $u Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany
- 700 1_
- $a Cyprová, Soňa $u Charles University, Motol Children's Hospital, Prague, Czech Republic $7 xx0314248
- 700 1_
- $a van den Berg, Henk $u Department of Pediatrics/Oncology, Emma Children's Hospital, University of Amsterdam, Amsterdam, the Netherlands
- 700 1_
- $a Hassenpflug, Wolf $u Pediatric Hematology and Oncology, University Hospital Eppendorf, Hamburg, Germany
- 700 1_
- $a Raciborska, Anna $u Department of Oncology and Surgical Oncology for Children and Youth, Mother and Child Institute, Warsaw, Poland $1 https://orcid.org/0000000326127934
- 700 1_
- $a Ek, Torben $u Childhood Cancer Center, Queen Silvia Children's Hospital, Gothenburg, Sweden $1 https://orcid.org/000000020518983X
- 700 1_
- $a Baumhoer, Daniel $u Bone Tumor Reference Center at the Institute of Medical Genetics and Pathology, University Hospital Basel and University of Basel, Basel, Switzerland $1 https://orcid.org/0000000221377507
- 700 1_
- $a Egerer, Gerlinde $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
- 700 1_
- $a Eich, Hans Theodor $u Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany
- 700 1_
- $a Renard, Marleen $u Pediatric Hematology and Oncology, University Hospital Leuven Gasthuisberg, Leuven Belgium
- 700 1_
- $a Hauser, Peter $u Head of the Pediatric Oncology and Transplantation Unit, Velkey László Child's Health Center, Borsod-Abaúj-Zemplén County University Teaching Hospital, Miskolc, Hungary $u 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000283078975
- 700 1_
- $a Burdach, Stefan $u Department of Pediatrics and Children's Cancer Research Center (CCRC), Technische Universität München, Munich, Germany $u British Columbia Cancer Research Centre, Vancouver, BC, Canada
- 700 1_
- $a Bovee, Judith $u Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands
- 700 1_
- $a Bonar, Fiona $u Douglass Hanly Moir Pathology, Macquarie Park, Australia $1 https://orcid.org/0000000168253336
- 700 1_
- $a Reichardt, Peter $u Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, Germany
- 700 1_
- $a Kruseova, Jarmila $u Charles University, Motol Children's Hospital, Prague, Czech Republic $1 https://orcid.org/0000000265767048
- 700 1_
- $a Hardes, Jendrik $u Clinic of Orthopedics, University Hospital Essen, West German Cancer Centre, Essen, Germany $1 https://orcid.org/0000000284082255
- 700 1_
- $a Kühne, Thomas $u Department of Oncology and Hematology, University Children's Hospital Basel, Basel, Switzerland $1 https://orcid.org/0000000273877028
- 700 1_
- $a Kessler, Torsten $u Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany $1 https://orcid.org/0000000176795362
- 700 1_
- $a Collaud, Stephane $u Department of Thoracic Surgery, Ruhrlandklinik, University Hospital Essen, Essen, Germany $1 https://orcid.org/0000000247491017
- 700 1_
- $a Bernkopf, Marie $u Department of Pediatrics, St Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Butterfaß-Bahloul, Trude $u Centre for Clinical Trials (ZKS) Muenster, University of Muenster, Muenster, Germany
- 700 1_
- $a Dhooge, Catharina $u Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Princess Elisabeth Children's Hospital, Ghent University, Ghent, Belgium $1 https://orcid.org/0000000299403672
- 700 1_
- $a Bauer, Sebastian $u Department of Medical Oncology, Sarcoma Center, University of Duisburg-Essen, Essen, Germany $u West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany $1 https://orcid.org/0000000159498120
- 700 1_
- $a Kiss, János $u Department of Orthopaedics, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Paulussen, Michael $u General Pediatrics, Oncology and Hematology, Vestische Kinder und Jugendklinik Datteln, Witten/Herdecke University, Datteln, Germany
- 700 1_
- $a Hong, Angela $u Chris O'Brien Lifehouse, Camperdown, Australia $u Sydney Medical School, University of Sydney, Sydney, Australia
- 700 1_
- $a Ranft, Andreas $u West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany $u Paediatrics III, University Hospital Essen, Essen, Germany $u German Consortium for Translational Cancer Research (DKTK), German Cancer Research Centre, Essen, Germany $1 https://orcid.org/0000000344247569
- 700 1_
- $a Timmermann, Beate $u West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany $u German Consortium for Translational Cancer Research (DKTK), German Cancer Research Centre, Essen, Germany $u Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), Essen, Germany
- 700 1_
- $a Rascon, Jelena $u Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania $u Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania $1 https://orcid.org/0000000344206943
- 700 1_
- $a Vieth, Volker $u Department of Clinical Radiology, Klinikum Ibbenbüren, Ibbenbüren, Germany
- 700 1_
- $a Kanerva, Jukka $u Hematology and Stem Cell Transplantation, New Children's Hospital, HUS Helsinki University Hospital, University of Helsinki, Helsinki, Finland
- 700 1_
- $a Faldum, Andreas $u Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany
- 700 1_
- $a Metzler, Markus $u Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany $1 https://orcid.org/0000000245231676
- 700 1_
- $a Hartmann, Wolfgang $u Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, Muenster, Germany $1 https://orcid.org/0000000276095021
- 700 1_
- $a Hjorth, Lars $u Department of Clinical Sciences, Skåne University Hospital, Lund, Sweden $1 https://orcid.org/0000000283027174
- 700 1_
- $a Bhadri, Vivek $u Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia $u Faculty of Medicine and Health, University of Sydney, Sydney, Australia
- 700 1_
- $a Dirksen, Uta $u West German Cancer Centre (WTZ) Network, Essen and Muenster, Germany $u Paediatrics III, University Hospital Essen, Essen, Germany $u German Consortium for Translational Cancer Research (DKTK), German Cancer Research Centre, Essen, Germany $1 https://orcid.org/0000000254357860
- 773 0_
- $w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 40, č. 21 (2022), s. 2307-2320
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35427190 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20240219134255 $b ABA008
- 999 __
- $a ok $b bmc $g 1854736 $s 1176467
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 40 $c 21 $d 2307-2320 $e 20220415 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
- LZP __
- $a Pubmed-20221017
